CN114224973A - Traditional Chinese medicine composition for treating diabetic ketosis - Google Patents
Traditional Chinese medicine composition for treating diabetic ketosis Download PDFInfo
- Publication number
- CN114224973A CN114224973A CN202210038899.0A CN202210038899A CN114224973A CN 114224973 A CN114224973 A CN 114224973A CN 202210038899 A CN202210038899 A CN 202210038899A CN 114224973 A CN114224973 A CN 114224973A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- medicine composition
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 title claims abstract description 32
- 240000000249 Morus alba Species 0.000 claims abstract description 32
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 32
- 239000008187 granular material Substances 0.000 claims abstract description 24
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 20
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 240000002948 Ophiopogon intermedius Species 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 claims abstract description 17
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 14
- 241000218989 Trichosanthes Species 0.000 claims abstract description 10
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 8
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 8
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 8
- 238000009472 formulation Methods 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- 239000000284 extract Substances 0.000 claims description 40
- 239000002994 raw material Substances 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 238000001914 filtration Methods 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 17
- 241000756943 Codonopsis Species 0.000 claims description 15
- 239000000341 volatile oil Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 12
- 238000009835 boiling Methods 0.000 claims description 11
- 238000002137 ultrasound extraction Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 239000004067 bulking agent Substances 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000001256 steam distillation Methods 0.000 claims description 5
- 241000007126 Codonopsis pilosula Species 0.000 claims description 4
- 241000893536 Epimedium Species 0.000 claims description 4
- 240000006079 Schisandra chinensis Species 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 210000003038 endothelium Anatomy 0.000 claims description 4
- 235000018905 epimedium Nutrition 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000008517 radix Trichosanthis Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 2
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 2
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 2
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 2
- 244000197580 Poria cocos Species 0.000 claims description 2
- 235000008599 Poria cocos Nutrition 0.000 claims description 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 2
- 235000006533 astragalus Nutrition 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 241000045403 Astragalus propinquus Species 0.000 claims 1
- 240000004638 Dendrobium nobile Species 0.000 claims 1
- 241000304195 Salvia miltiorrhiza Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 70
- 210000004369 blood Anatomy 0.000 abstract description 47
- 239000008280 blood Substances 0.000 abstract description 47
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 14
- 230000036039 immunity Effects 0.000 abstract description 13
- 230000004060 metabolic process Effects 0.000 abstract description 10
- 230000004087 circulation Effects 0.000 abstract description 5
- 210000004556 brain Anatomy 0.000 abstract description 4
- 230000001603 reducing effect Effects 0.000 description 26
- 210000004072 lung Anatomy 0.000 description 20
- 230000001737 promoting effect Effects 0.000 description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 14
- 241001523681 Dendrobium Species 0.000 description 11
- 229920002527 Glycogen Polymers 0.000 description 10
- 229940096919 glycogen Drugs 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 230000035922 thirst Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 8
- 241001076416 Dendrobium tosaense Species 0.000 description 7
- 235000017784 Mespilus germanica Nutrition 0.000 description 7
- 244000182216 Mimusops elengi Species 0.000 description 7
- 235000000560 Mimusops elengi Nutrition 0.000 description 7
- 235000007837 Vangueria infausta Nutrition 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 6
- 206010022489 Insulin Resistance Diseases 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 5
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 239000009636 Huang Qi Substances 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 208000007976 Ketosis Diseases 0.000 description 4
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 240000006023 Trichosanthes kirilowii Species 0.000 description 4
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000001914 calming effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 3
- 229910001626 barium chloride Inorganic materials 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 3
- -1 puerarin lignan glycoside Chemical class 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 244000132619 red sage Species 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 240000005717 Dioscorea alata Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010023379 Ketoacidosis Diseases 0.000 description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- 206010027417 Metabolic acidosis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 235000004879 dioscorea Nutrition 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 230000000225 effect on diabetes Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- NSSALFVIQPAIQK-FPLPWBNLSA-N (Z)-2-Nonen-1-ol Chemical compound CCCCCC\C=C/CO NSSALFVIQPAIQK-FPLPWBNLSA-N 0.000 description 1
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- BHVJSLPLFOAMEV-UHIFYLTQSA-M 20-Epibryonolic acid Natural products C([C@H]1[C@]2(C)CC3)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@]2(C)C1=C3[C@@]2(C)CC[C@H](O)C(C)(C)[C@@H]2CC1 BHVJSLPLFOAMEV-UHIFYLTQSA-M 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- SMRPGWBDLOQHOS-UHFFFAOYSA-N 5-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[[9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]oxane-2-carboxylic acid Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(C(O)C2O)C(O)=O)OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4=O)C)(C)CC3)(C)CC2)(C)CO)OC(CO)C(O)C1O SMRPGWBDLOQHOS-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 241001573366 Astragalus membranaceus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- BHVJSLPLFOAMEV-UHFFFAOYSA-N Bryonolic acid Natural products C1CC2(C)C3CC(C)(C(O)=O)CCC3(C)CCC2(C)C2=C1C1(C)CCC(O)C(C)(C)C1CC2 BHVJSLPLFOAMEV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- LNSXRXFBSDRILE-UHFFFAOYSA-N Cucurbitacin Natural products CC(=O)OC(C)(C)C=CC(=O)C(C)(O)C1C(O)CC2(C)C3CC=C4C(C)(C)C(O)C(O)CC4(C)C3(C)C(=O)CC12C LNSXRXFBSDRILE-UHFFFAOYSA-N 0.000 description 1
- CVKKIVYBGGDJCR-SXDZHWHFSA-N Cucurbitacin B Natural products CC(=O)OC(C)(C)C=CC(=O)[C@@](C)(O)[C@@H]1[C@@H](O)C[C@]2(C)C3=CC[C@@H]4C(C)(C)C(=O)[C@H](O)C[C@@]4(C)[C@@H]3CC(=O)[C@@]12C CVKKIVYBGGDJCR-SXDZHWHFSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 101710196208 Fibrinolytic enzyme Proteins 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023388 Ketonuria Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000023668 Pharyngeal disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 108010021119 Trichosanthin Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229960004266 acetylcholine chloride Drugs 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229940045511 barium chloride Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 150000001904 cucurbitacins Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- PIGAXYFCLPQWOD-UHFFFAOYSA-N dihydrocucurbitacin I Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(O)C)C(O)CC3(C)C1CC=C1C2C=C(O)C(=O)C1(C)C PIGAXYFCLPQWOD-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002892 effect on hypertension Effects 0.000 description 1
- 230000000214 effect on organisms Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 230000003087 glucogenic effect Effects 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000024972 intestine smooth muscle contraction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 230000010117 myocardial relaxation Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- PPRSVUXPYPBULA-UHFFFAOYSA-N saponin A Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O PPRSVUXPYPBULA-UHFFFAOYSA-N 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000000051 wattle Anatomy 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine composition for treating diabetic ketosis, and relates to the technical field of diabetes treatment. The traditional Chinese medicine composition comprises the following components in parts by weight: 10-30 parts of mulberry leaf, 30-50 parts of kudzu root, 20-30 parts of trichosanthes root, 15-30 parts of dwarf lilyturf tuber and 20-30 parts of wolfberry fruit. The traditional Chinese medicine composition can obviously reduce the blood sugar level of an organism, improve the immunity of the organism, improve the brain circulation and restore the normal metabolism of the organism, and has small side effect, thereby effectively treating diabetic ketosis and diabetes. The preparation formulation of the traditional Chinese medicine composition is oral liquid or granules, and the medicine effect of the traditional Chinese medicine composition can be better and faster by preparing the traditional Chinese medicine composition into the oral liquid or granules, so that the traditional Chinese medicine composition has better treatment effect on the diabetic ketosis.
Description
Technical Field
The invention relates to the technical field of diabetes treatment, and particularly relates to a traditional Chinese medicine composition for treating diabetic ketosis.
Background
Diabetic ketosis is the most common acute complication of diabetic patients, and people with severe ketoacidosis suffer from disturbance of consciousness to coma to different degrees, and if the patients are not cured in time, the patients die. Causes of diabetic ketosis include: the insulin treatment of type 1 diabetes patients is interrupted or the dosage is insufficient, the type 2 diabetes patients are in various stress (response to strong stimulation on body or spirit), the metabolic disturbance of diabetes is aggravated, the lipolysis is accelerated, the generation of intermediate metabolite ketone bodies (acetoacetic acid, hydroxybutyric acid and acetone) is increased and accelerated, the tissue utilization is exceeded, and the blood ketone is increased. Diabetic Ketoacidosis (DKA) refers to a group of syndromes of pathological changes such as hyperglycemia, hyperketosis, ketonuria, dehydration, electrolyte disorder, metabolic acidosis and the like caused by obvious insulin deficiency and inappropriate increase of glucogenic hormone under the action of various inducers of diabetic patients, and is one of the common emergencies in internal medicine. At present, more medicines for treating diabetic ketoacidosis are mainly western medicines, and the defects of poor treatment effect and great side effect exist.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating diabetic ketosis, which can obviously reduce the blood sugar level of an organism, improve the immunity of the organism, improve the brain circulation and restore the normal metabolism of the organism, and has small side effect, thereby effectively treating the diabetic ketosis and diabetes.
The technical problem to be solved by the invention is realized by adopting the following technical scheme.
The invention provides a traditional Chinese medicine composition for treating diabetic ketosis, which comprises the following raw materials in parts by weight: 10-30 parts of mulberry leaf, 30-50 parts of kudzu root, 20-30 parts of trichosanthes root, 15-30 parts of dwarf lilyturf tuber and 20-30 parts of wolfberry fruit.
The traditional Chinese medicine composition for treating diabetic ketosis of the embodiment of the invention at least has the following beneficial effects:
in the invention, deoxynojirimycin and ecdysterone in mulberry leaves respectively regulate blood sugar from different aspects, wherein the deoxynojirimycin inhibits the activity of alpha-glucosidase, reduces the absorption of sugar in food, inhibits hepatic glycogenolysis, increases insulin sensitivity and further reduces the blood sugar of an organism; ecdysterone is mainly used for promoting glucose to synthesize glycogen so as to reduce blood sugar. The flavonoid substances in the kudzuvine root can also reduce blood sugar, and when the kudzuvine root and the mulberry leaf are used together, a new blood sugar reducing substance can be generated in a machine body, so that the blood sugar reducing effects of the kudzuvine root and the mulberry leaf are further improved. The trichosanthes root and the dwarf lilyturf tuber are used together to synchronously regulate the heart, the stomach and the lung, can treat both symptoms and root causes, and further enhance the treatment effect on the diabetes. The radix ophiopogonis is, the mulberry leaves and the radix puerariae are used together, glucose is promoted to synthesize glycogen, absorption of the glycogen is reduced, and the glucose are synchronously regulated, so that the glucose reducing effect is better. The fructus Lycii has effects of invigorating qi, nourishing blood, and nourishing liver and kidney. The medlar fruit can repair the body, supplement nutrition, reduce blood sugar, restore the normal metabolism of the body and repair the damaged part of the body, thereby having better treatment effect on diabetes or diabetic ketosis.
The invention can promote the drug effects of the raw materials to each other through the reasonable proportion of the raw materials, nourish the organism while treating, thereby ensuring better treatment effect, and the raw materials can be eaten with little side effect.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
It should be noted that the embodiments and features of the embodiments in the present application may be combined with each other without conflict. The present invention will be described in detail below with reference to specific examples.
A traditional Chinese medicine composition for treating diabetic ketosis comprises the following raw materials in parts by weight: 10-30 parts of mulberry leaf, 30-50 parts of kudzu root, 20-30 parts of trichosanthes root, 15-30 parts of dwarf lilyturf tuber and 20-30 parts of wolfberry fruit.
Mulberry leaves, namely dry leaves of mulberry of Moraceae, also known as mulberry, wattle, mulberry, yellow mulberry leaves and the like, are produced in most regions in China, and deoxynojirimycin extracted from mulberry leaves and flavonoid extracted from kudzu roots are combined to form a new substance-pancreas washing and glucose removing substance, which is suitable for treating blood sugar and blood fat, inflammation and the like. The mulberry leaves are bitter and sweet in taste and cold in nature, enter lung and liver meridians, have the effects of dispelling wind and heat, clearing lung and moistening dryness, calming liver and improving eyesight, and cooling blood and stopping bleeding, and are mainly used for treating wind and heat type common cold, early epidemic febrile disease, cough due to lung heat, dizziness due to liver-yang hyperactivity, conjunctival congestion and coma, and hemoptysis and hematemesis caused by recklessly blood heat. The mulberry leaves have the spasmolytic effect; the mulberry leaf decoction has the effect of resisting pathogenic microorganisms, has certain inhibiting effect on staphylococcus aureus, beta hemolytic streptococcus, diphtheria bacillus, escherichia coli and the like in vitro tests, and can also kill leptospira; has anti-inflammatory effect; the ecdysterone contained in the medicine has the function of reducing blood sugar on the rise of blood sugar induced by various methods, and can promote the conversion of glucose into glycogen without changing the blood sugar of normal animals; the mulberry leaf extract has the function of reducing blood pressure, and is injected into femoral vein after anesthesia of dogs, so that temporary blood pressure reduction occurs, but respiration is not influenced; the composition has the effects of stimulating animal estrus uterus and inhibiting intestinal muscle of mice; has effects of reducing blood lipid and promoting urination.
Kudzu vine root, cool in nature, sweet and pungent in taste, contains isoflavone components of puerarin, puerarin lignan glycoside, soybean flavone glycoside, beta-sitosterol and arachidic acid, contains a large amount of starch (the content of fresh kudzu vine root is 19-20%), has the effects of relieving exterior syndrome, allaying fever, promoting fluid production, promoting eruption, invigorating yang and stopping diarrhea, and is used for treating exogenous fever and headache, hypertension neck pain, thirst, diabetes, measles without adequate eruption, dysentery with heat and diarrhea. The isoflavone compound puerarin in radix Puerariae has certain curative effect on hypertension, hyperlipemia, hyperglycemia and cardiovascular and cerebrovascular diseases. The product has effects in nourishing myocardium, dilating blood vessel, improving oxygen metabolism of myocardium, improving microcirculation, reducing vascular resistance, and increasing blood flow, and can be used for preventing and treating myocardial ischemia, myocardial infarction, arrhythmia, hypertension, and arteriosclerosis. The acetone extract of radix Puerariae has effect in restoring body temperature, and can be used for treating various fevers. Puerarin has obvious effect of lowering blood sugar, and flavonoid compounds contained in radix Puerariae has effect of lowering blood lipid, reducing serum cholesterol, reducing triglyceride, and improving cerebral circulation, and can be used for treating hyperglycemia and hyperlipemia. The radix Puerariae powder has effects of regulating human body function, improving body constitution, improving organism disease resistance, resisting aging, prolonging life, and keeping youth.
The trichosanthes root, a little cold in nature, sweet and slightly bitter in taste, enters lung channel and stomach channel, has the specific efficacies of clearing heat and purging fire, promoting the production of body fluid to quench thirst, expelling pus and reducing swelling, and is mainly used for treating: for fever thirst, diabetes, jaundice, lung dryness, hemoptysis, carbuncle and hemorrhoid, it is often used in combination with yin-nourishing herbs to treat both symptoms and root causes. Trichosanthis radix contains starch and saponin, bryonolic acid, cucurbitacin, arginine, aspartic acid, fructose, xylose, etc., and also contains trichosanthin and various amino acids.
Radix Ophiopogonis, sweet in taste, slightly bitter and slightly cold in nature, has effects of nourishing yin, promoting fluid production, moistening lung and clearing heart, and can be used for treating lung dryness and dry cough, consumptive disease and cough, body fluid consumption and thirst, vexation and insomnia, internal heat and thirst, intestine dryness and constipation, and pharyngeal diphtheria. The radix ophiopogonis can improve the tolerance of myocardium to hypoxia during hypoxia or ischemia; enhancing myocardial contraction force, increasing cardiac output and coronary flow; can be used for treating arrhythmia caused by epinephrine, barium chloride, and aconitine; the small intestine smooth muscle contraction caused by acetylcholine or barium chloride has antagonism; the pentobarbital sodium hypnotic has synergistic effect, and the sedative effect on the chlorpromazine is enhanced; reducing the level of free fatty acid in serum and reducing the range of myocardial infarction; has effects in reducing blood sugar, promoting islet cell recovery, and increasing liver glycogen.
Fructus Lycii has effects of invigorating qi, nourishing blood, and nourishing liver and kidney, and can be used for treating anemia due to deficiency of both qi and blood, puerperal hemorrhage, postoperative weakness, sallow complexion, thick and white tongue fur, myasthenia of limbs, listlessness, dizziness, blurred vision, tinnitus, dreaminess, cardiopalmus, chest distress, short breath, soreness of waist and knees, night sweat, etc.; has effects in improving skin elasticity, resisting aging, resisting oxidation, lowering hypertension, hyperlipemia and triglyceride, enhancing immunity, protecting liver, and inhibiting cancer cell regeneration and diffusion.
In this embodiment, both ecdysterone and deoxynojirimycin in mulberry leaf can reduce blood sugar, wherein ecdysterone can promote the conversion of glucose into glycogen, and deoxynojirimycin can inhibit the activity of alpha-glucosidase and delay the conversion of oligosaccharide (sucrose) such as disaccharide in food into monosaccharide (glucose), thereby reducing the absorption of sugar in food, reducing postprandial blood sugar, inhibiting the activity of glycogen phosphorylase, inhibiting the decomposition of liver glycogen into glucose, controlling fasting blood sugar, increasing insulin sensitivity and improving insulin resistance. And the deoxynojirimycin can be combined with a flavone substance in the root of kudzu vine to form a new substance-insulin-washing glucose, so that the blood sugar level in vivo is further reduced. The flavonoids in the kudzuvine root can also reduce blood fat and cholesterol, improve cerebral circulation and regulate the blood fat and blood sugar level in vivo. The radix Puerariae powder can also enhance organism immunity, recover organism metabolism, and has certain therapeutic effect on diabetes. The radix trichosanthis mainly aims at the lung and the stomach, improves the symptoms of thirst and diabetes by regulating the stomach and the intestine, is used together with the radix ophiopogonis to synchronously regulate the heart, the stomach and the lung, can treat both symptoms and root causes, and further enhances the treatment effect on the diabetes. The radix ophiopogonis can also promote islet cell recovery, so that sugar metabolism is normal, and the generation of ketone bodies is reduced, thereby effectively treating ketosis. The radix ophiopogonis is, the mulberry leaves and the radix puerariae are used together, glucose is promoted to synthesize glycogen, absorption of the glycogen is reduced, and the glucose are synchronously regulated, so that the glucose reducing effect is better. The medlar has the effects of benefiting qi, nourishing blood, tonifying liver and kidney, can be used for repairing the organism to supplement nutrition, reducing blood sugar, recovering normal metabolism of the organism and repairing the damaged part of the organism under the condition of ketoacidosis, and further has better treatment effect on diabetes or diabetic ketosis.
The embodiment can mutually promote the drug effects of the raw materials through the reasonable proportion of the raw materials, nourish the organism while treating, thereby ensuring better treatment effect, and the raw materials can be eaten with small side effect.
The traditional Chinese medicine composition of the embodiment also comprises 15-20 parts of radix pseudostellariae, 10-20 parts of dendrobium and 20-30 parts of codonopsis pilosula according to parts by weight.
Radix pseudostellariae is neutral in nature, sweet in taste and slightly bitter in taste, enters spleen channels and lung channels, and has the effects of tonifying qi and spleen, promoting the production of body fluid and moistening lung. Belongs to the category of deficiency-tonifying drugs, can improve the immunologic function of human bodies, improve the cardiac function of human bodies, treat cough due to lung deficiency, anorexia due to spleen deficiency, palpitation, spontaneous perspiration and mental fatigue, and is used for treating weakness due to spleen deficiency, weakness after illness, deficiency of qi and yin, spontaneous perspiration, thirst, dry cough due to lung dryness. Has stable drug property, and is suitable for long-term administration. Is rich in saponin and fructose, and has effects of relieving fatigue and enhancing body resistance. Contains radix Pseudostellariae polysaccharide, and various amino acids and microelements necessary for human body. Radix Pseudostellariae polysaccharide has anti-stress and anti-fatigue effects; can improve immunity, promote lymphocyte proliferation, and improve spleen deficiency symptoms; has stable SOD-like effect of non-enzyme except superoxide radical. The sugar alcohol component has strong antibacterial effect. Radix Pseudostellariae saponin A has antiviral effect. The phospholipid component has the effects of improving immunity, protecting cell integrity, reducing blood lipid, delaying aging, strengthening brain, strengthening essence and preventing cerebrovascular diseases.
The herba Dendrobii contains polysaccharide, alkaloid, amino acids, etc., and contains microelements such as calcium, potassium, sodium, magnesium, zinc, ferrum, manganese, selenium, copper, chromium, nickel, etc. The polysaccharide content is 18.974% and the total alkaloid content is 0.03% as identified by medicinal plants in Chinese pharmaceutical institute, and the product has effects of improving immunity and treating eye, pharynx, lung, stomach, intestine, and kidney diseases. The composition has effects in lowering blood sugar, inhibiting cardiovascular diseases, enhancing immunity, and resisting cancer; the tea substitute can clear and moisten throat, clear and improve eyesight, relieve summer heat and tonify qi, nourish stomach and clear heat. The dendrobium officinale can promote gastric secretion, enhance small intestine peristalsis, help gastrointestinal digestion and facilitate softening stool and defecation, and the dendrobium officinale juicing can obviously improve the gastric acid level, so that the concentration of gastrin in blood is increased, and the chronic gastritis is effectively treated. The dendrobium officinale can obviously improve the levels of superoxide dismutase and HYP of a human body and obviously reduce the oxidation function of the body, thereby playing a role in resisting aging. The Dendrobium officinale has dual-effect of reducing blood sugar, can increase insulin secretion, and can improve insulin resistance. The dendrobium officinale contains polysaccharide which has the effects of resisting cell mutation, eliminating aging and death cells in vivo and stabilizing the physiological state of an organism, so that the dendrobium officinale has stronger antitumor activity. The dendrobium officinale can enhance the immunity of people, resist the invasion of viruses and reduce the morbidity of diseases.
Radix Codonopsis has effects of invigorating spleen, replenishing qi, quenching thirst, invigorating spleen, benefiting lung, nourishing blood, promoting fluid production, resisting cancer, lowering blood pressure, resisting anoxia, resisting aging, resisting ulcer, enhancing immunity, regulating gastrointestinal motility, inhibiting gastric acid secretion, and reducing pepsin activity. The radix Codonopsis saponin has effects of regulating intestinal tract, and resisting influence of acetylcholine, 5-hydroxytryptamine, histamine and barium chloride on intestinal tract. The radix Codonopsis extract can increase macrophage number, enhance activity of multiple enzymes, enhance phagocytosis of chicken erythrocyte by macrophage, and promote DNA synthesis of spleen lymphocyte. Radix Codonopsis can increase hemoglobin and promote erythropoiesis; can improve the resistance of the organism to harmful stimulation; has the function of resisting hypoxia at normal pressure, and obviously increases the content of myocardial glycogen, succinate dehydrogenase and lactate dehydrogenase; has effects in lowering blood pressure, improving myocardial relaxation, dilating peripheral blood vessel, and reducing coronary artery perfusion resistance, thereby improving myocardial ischemia; inhibiting platelet aggregation, reducing serum low density lipoprotein, triglyceride and cholesterol content in hyperlipidemia, improving fibrinolytic enzyme activity, and remarkably inhibiting platelet aggregation rate and plasma thromboxane TXB2 level.
Radix pseudostellariae has the effects of tonifying qi and spleen, promoting the production of body fluid and moistening lung, is stable in medicine property and can improve the immunity of the organism; the dendrobium can improve the immunity of human bodies, increase the secretion of insulin and improve the insulin resistance; radix Codonopsis has effects of invigorating spleen, replenishing qi, quenching thirst, invigorating spleen, benefiting lung, nourishing blood, promoting fluid production, increasing hemoglobin, reducing blood lipid, and reducing cholesterol. Several of the above raw materials are matched for use, so that the Chinese medicinal composition has better tonifying effect on organisms, increases insulin secretion, improves insulin resistance and further better regulates blood sugar.
The traditional Chinese medicine composition of the embodiment also comprises 30-50 parts of astragalus membranaceus, 30-50 parts of Chinese yam, 30-50 parts of poria cocos, 10-30 parts of epimedium, 20-30 parts of salvia miltiorrhiza, 30-50 parts of endothelium corneum gigeriae galli, 30-50 parts of dark plum and 20-30 parts of schisandra chinensis in parts by weight.
Radix astragali has effects of invigorating qi, invigorating yang, consolidating superficial resistance, arresting sweating, inducing diuresis, relieving swelling, promoting fluid production, nourishing blood, activating stagnancy, relieving arthralgia, removing toxic substance, expelling pus, healing sore, and promoting granulation. Rhizoma Dioscoreae has effects of invigorating spleen and stomach, promoting fluid production, benefiting lung, invigorating kidney and arresting seminal emission. Poria has effects of promoting diuresis, eliminating dampness, invigorating spleen, and calming heart. Herba Epimedii has effects of invigorating kidney yang, strengthening tendons and bones, and dispelling pathogenic wind and dampness. The red sage root has the effects of removing blood stasis, relieving pain, promoting blood circulation, relieving dysmenorrheal, clearing away heart-fire and relieving restlessness. Endothelium corneum Gigeriae Galli has effects of invigorating stomach, resolving food stagnation, astringing essence and relieving enuresis. The dark plum has the effects of astringing lung, astringing intestine, promoting fluid production and calming ascaris. Fructus Schisandrae has astringent, qi invigorating, salivation promoting, kidney invigorating, and heart calming effects. The medicinal materials are matched with the raw materials, so that the sugar metabolism process can be further enhanced, and the sugar metabolism is recovered to be normal; further enhance the metabolism of organisms and restore the microcirculation in the bodies; further nourishing spleen, stomach and kidney, reducing metabolic disturbance caused by physical weakness, thereby having better treatment effect on diabetic ketosis.
In this embodiment, the dosage form of the Chinese medicinal composition is oral liquid or granules. The two preparation types can better exert the drug effect of the drug, thereby improving the drug treatment effect and accelerating the drug treatment effect.
In detail, the preparation method of the oral liquid comprises the following steps:
adding 2000mL of 1000-fold water into folium mori, radix puerariae, radix trichosanthis, radix ophiopogonis, fructus lycii, radix pseudostellariae, dendrobe and radix codonopsis pilosulae for decoction, boiling for 10-15min by strong fire, decocting for 20-30min by slow fire, filtering to obtain a first decoction and filter residue, adding 1000mL of 500-fold water into the filter residue for decoction, decocting for 15-25min by slow fire after boiling by strong fire, filtering to obtain a second decoction, and combining the two decoctions to obtain the Chinese medicinal composition.
The oral liquid is prepared by decocting the raw materials in water, the preparation method is simple, and the medicine can better and more quickly exert curative effect in vivo. 1000-2000mL of water is added for decoction, so that the effective components in the raw materials can be better extracted, and the medicinal effect is better. The first time of decoction is carried out by strong fire, so that the raw materials are convenient to soak quickly, and then the decoction is carried out by slow fire, so that the effective components in the raw materials are more convenient to extract, and the effective components can be better extracted by decocting for 10-15min by strong fire and 20-30min by slow fire. Adding water into the filter residue obtained after the first decoction for secondary decoction, directly turning to slow fire after the filter residue is boiled by strong fire during the secondary decoction, and because the filter residue is completely soaked at the moment, the filter residue is gelatinized by using the strong fire for decoction again, so that the extraction effect is influenced, the effective components which are not completely extracted in the filter residue can be further extracted by selecting the secondary decoction, and the two decoctions are combined, so that the concentration of the effective components in the decoctions is improved, and the effect is better after the decoction is used.
In detail, the preparation method of the granules comprises:
pulverizing radix Puerariae, radix Pseudostellariae and radix Codonopsis respectively, pulverizing to obtain powder with particle diameter of 50-60 μm, mixing the powder with Trichosanthis radix, adding 5-10 times of 70-80% ethanol, performing ultrasonic extraction at 40-60KHz for 20-30min, filtering the extractive solution, recovering ethanol to obtain extractive solution, and concentrating at 50-60 deg.C to obtain first soft extract with relative density of 1-1.23; adding water into folium Mori, radix Ophiopogonis and herba Dendrobii, steam distilling at 100-; decocting fructus Lycii in water for 1-2 times, each time for 1-2 hr to obtain decoction, and vacuum concentrating the decoction to obtain second soft extract; mixing the first soft extract, the volatile oil extract and the second soft extract, adding filler, stirring at 100-150r/min for 10-20min, drying at 50-60 deg.C for 15-30min, and making into granule.
The ultrasonic extraction is carried out after part of raw materials are crushed, the crushing is beneficial to increasing the contact area of the raw materials and the ethanol, and the ethanol can better permeate or leach the raw materials during extraction, so that the active ingredients in the raw materials can be better extracted. The grain size is selected to be 50-60 mu m, and the extraction effect of the ethanol on the raw materials is better under the grain size. Because the dosage and concentration of the ethanol can influence the extraction effect, through a plurality of experiments, the 5-10 times of ethanol with the volume fraction of 70-80% is obtained, and the extraction effect of the raw materials is the best. The ultrasonic frequency and ultrasonic time can also influence the extraction effect, and the effective components in the raw materials can be separated out better in the ultrasonic extraction for 20-30min at 40-60 KHz. Concentrating the extractive solution at 50-60 deg.C to relative density of 1-1.23 to obtain first soft extract, which can increase the concentration of effective components in the first soft extract, and has better medicinal effect and therapeutic effect at high concentration. The mulberry leaf, the dwarf lilyturf tuber and the dendrobium are added with water for steam distillation, the active ingredients of the mulberry leaf, the dwarf lilyturf tuber and the dendrobium are mainly volatile oil, so that the extraction rate of the volatile oil is high, and the volatile oil can be completely extracted by steam distillation at 100-130 ℃ for 2-5 h. The medlar fruits are decocted by adding water, active ingredients can be extracted during decoction, the operation is simple, the process time is shortened, the obtained decoction liquid is concentrated in vacuum to obtain second thick paste, the vacuum concentration speed is high, the effect is good, and the concentration of the active ingredients can be improved through concentration.
Mixing the first thick paste, the volatile oil extract and the second thick paste to obtain the traditional Chinese medicine composition, adding the filler to increase the weight or volume of the traditional Chinese medicine composition, thus reducing dosage deviation during medication, stirring at 100-. Drying at 50-60 deg.C for 15-30min to reduce water content, making into preparation, drying, and making into granule. The granule can be administered orally with water, and is convenient for carrying.
In detail, the particle size of the radices trichosanthis is 70-90 μm, under the particle size, the effective components in the radices trichosanthis are more convenient to extract, thereby leading the efficacy of the traditional Chinese medicine composition to be better.
Optionally, the filler is one of starch, powdered sugar and dextrin. The filler can increase the weight or volume of the raw materials, reduce the deviation of the main medicament dosage and ensure that the obtained granules have better uniformity.
During steam distillation, the ratio of the mass of water to the total mass of the mulberry leaves, the dwarf lilyturf roots and the dendrobium stems is (4-7): 1. the mass ratio is limited because the evaporation speed of water is high during steam distillation, and the active ingredients in the raw materials are prevented from being not completely extracted when the water is evaporated to dryness.
The features and properties of the present invention are described in further detail below with reference to examples.
Example 1
A traditional Chinese medicine composition for treating diabetic ketosis comprises the following raw materials:
15g of mulberry leaf, 35g of kudzu root, 25g of trichosanthes root, 20g of dwarf lilyturf tuber and 25g of wolfberry fruit.
In this embodiment, the dosage form of the Chinese medicinal composition is oral liquid, and the preparation method of the oral liquid comprises:
decocting folium Mori, radix Puerariae, Trichosanthis radix, radix Ophiopogonis, and fructus Lycii with 1000mL of water, boiling with strong fire for 12min, decocting with slow fire for 25min, filtering to obtain first decoction and residue, decocting the residue with 500mL of water, boiling with strong fire, decocting with slow fire for 20min, filtering to obtain second decoction, and mixing the decoctions.
Example 2
A traditional Chinese medicine composition for treating diabetic ketosis comprises the following raw materials:
15g of mulberry leaf, 35g of kudzu root, 25g of trichosanthes root, 20g of dwarf lilyturf tuber and 25g of wolfberry fruit.
In this embodiment, the dosage form of the Chinese medicinal composition is granules, and the preparation method of the granules includes:
mixing radix Puerariae and Trichosanthis radix, adding 8 times of 75% ethanol, performing ultrasonic extraction at 50KHz for 25min, filtering the extractive solution, recovering ethanol to obtain extractive solution, and concentrating the extractive solution at 55 deg.C to relative density of 1.13 to obtain first soft extract; steam distilling folium Mori and radix Ophiopogonis with water at 120 deg.C for 3 hr, and filtering to obtain volatile oil extract; decocting fructus Lycii in water for 2 times, each time for 1.5 hr, to obtain decoction, and vacuum concentrating the decoction to obtain second soft extract; mixing the first soft extract, the volatile oil extract, and the second soft extract, adding bulking agent, drying at 55 deg.C for 20min, drying, and making into granule.
Example 3
A traditional Chinese medicine composition for treating diabetic ketosis comprises the following raw materials:
10g of mulberry leaf, 30g of kudzu vine root, 20g of trichosanthes root, 15g of dwarf lilyturf tuber, 20g of wolfberry fruit, 15g of radix pseudostellariae, 10g of dendrobium and 20g of codonopsis pilosula.
In this embodiment, the dosage form of the Chinese medicinal composition is oral liquid, and the preparation method of the oral liquid comprises:
adding 1000mL of water into folium Mori, radix Puerariae, Trichosanthis radix, radix Ophiopogonis, fructus Lycii, radix Pseudostellariae, herba Dendrobii and radix Codonopsis, decocting for 10min with strong fire, decocting for 20min with slow fire, filtering to obtain first decoction and residue, adding 500mL of water into residue, decocting for 15min with slow fire after boiling with strong fire, filtering to obtain second decoction, and mixing the two decoctions.
Example 4
A traditional Chinese medicine composition for treating diabetic ketosis comprises the following raw materials:
30g of mulberry leaf, 50g of kudzuvine root, 30g of Mongolian snakegourd root, 30g of dwarf lilyturf tuber, 30g of medlar, 20g of heterophylly falsestarwort root, 20g of dendrobium and 30g of pilose asiabell root.
In this embodiment, the dosage form of the Chinese medicinal composition is oral liquid, and the preparation method of the oral liquid comprises:
adding 2000mL of water into folium mori, radix puerariae, radix trichosanthis, radix ophiopogonis, fructus lycii, radix pseudostellariae, dendrobe and radix codonopsis pilosulae for decoction, firstly decocting the mixture for boiling for 15min by strong fire, then decocting the mixture for 30min by slow fire, filtering the mixture to obtain a first decoction and filter residue, adding 1000mL of water into the filter residue for decoction, decocting the mixture for boiling by strong fire, then decocting the mixture for 25min by slow fire, filtering the mixture to obtain a second decoction, and combining the two decoctions to obtain the Chinese medicinal composition.
Example 5
A traditional Chinese medicine composition for treating diabetic ketosis comprises the following raw materials:
20g of mulberry leaf, 35g of kudzuvine root, 25g of mongolian snakegourd root, 20g of dwarf lilyturf tuber, 25g of medlar, 18g of heterophylly falsestarwort root, 15g of dendrobium, 25g of pilose asiabell root, 30g of membranous milkvetch root, 30g of common yam rhizome, 30g of Indian buead, 10g of epimedium herb, 20g of danshen root, 30g of chicken's gizzard-membrane, 30g of dark plum fruit and 20g of Chinese magnoliavine fruit.
In this embodiment, the dosage form of the Chinese medicinal composition is oral liquid, and the preparation method of the oral liquid comprises:
adding 1500mL of water into the raw materials, decocting with strong fire for boiling for 12min, decocting with slow fire for 23min, filtering to obtain a first decoction and a filter residue, adding 800mL of water into the filter residue, decocting with strong fire for boiling, decocting with slow fire for 20min, filtering to obtain a second decoction, and mixing the two decoctions to obtain the final product.
Example 6
A traditional Chinese medicine composition for treating diabetic ketosis comprises the following raw materials:
10g of mulberry leaf, 30g of kudzu vine root, 20g of trichosanthes root, 15g of dwarf lilyturf tuber, 20g of wolfberry fruit, 15g of radix pseudostellariae, 10g of dendrobium and 20g of codonopsis pilosula.
In this embodiment, the dosage form of the Chinese medicinal composition is granules, and the preparation method of the granules includes:
mixing radix Puerariae, radix Pseudostellariae, radix Codonopsis and Trichosanthis radix, adding 5 times of 70% ethanol, performing ultrasonic extraction at 40KHz for 20min, filtering the extractive solution, recovering ethanol to obtain extractive solution, and concentrating the extractive solution at 50 deg.C to relative density of 1 to obtain first soft extract; steam distilling folium Mori, radix Ophiopogonis and herba Dendrobii with water at 100 deg.C for 2 hr, and filtering to obtain volatile oil extract; decocting fructus Lycii in water for 1 time, each time for 1 hr, to obtain decoction, and vacuum concentrating the decoction to obtain second soft extract; mixing the first soft extract, the volatile oil extract, and the second soft extract, adding bulking agent, drying at 50 deg.C for 15min, drying, and making into granule.
Example 7
A traditional Chinese medicine composition for treating diabetic ketosis comprises the following raw materials:
30g of mulberry leaf, 50g of kudzuvine root, 30g of Mongolian snakegourd root, 30g of dwarf lilyturf tuber, 30g of medlar, 20g of heterophylly falsestarwort root, 20g of dendrobium and 30g of pilose asiabell root.
In this embodiment, the dosage form of the Chinese medicinal composition is granules, and the preparation method of the granules includes:
mixing radix Puerariae, radix Pseudostellariae, radix Codonopsis and Trichosanthis radix, adding 10 times of 80% ethanol, performing ultrasonic extraction at 60KHz for 30min, filtering the extractive solution, recovering ethanol to obtain extractive solution, and concentrating the extractive solution at 60 deg.C to relative density of 1.23 to obtain first soft extract; steam distilling folium Mori, radix Ophiopogonis and herba Dendrobii with water at 130 deg.C for 5 hr, and filtering to obtain volatile oil extract; decocting fructus Lycii in water for 2 times, each time for 2 hr, to obtain decoction, and vacuum concentrating the decoction to obtain second soft extract; mixing the first soft extract, the volatile oil extract, and the second soft extract, adding bulking agent, drying at 60 deg.C for 30min, drying, and making into granule.
Example 8
A traditional Chinese medicine composition for treating diabetic ketosis comprises the following raw materials:
20g of mulberry leaf, 35g of kudzuvine root, 25g of mongolian snakegourd root, 20g of dwarf lilyturf tuber, 25g of medlar, 18g of heterophylly falsestarwort root, 15g of dendrobium, 25g of pilose asiabell root, 50g of membranous milkvetch root, 50g of common yam rhizome, 30g of Indian buead, 30g of epimedium herb, 30g of danshen root, 50g of chicken's gizzard-membrane, 50g of dark plum fruit and 30g of Chinese magnoliavine fruit.
In this embodiment, the dosage form of the Chinese medicinal composition is granules, and the preparation method of the granules includes:
pulverizing radix Puerariae, radix Pseudostellariae, radix Codonopsis, radix astragali, rhizoma Dioscoreae, Poria, herba Epimedii, Saviae Miltiorrhizae radix, endothelium corneum Gigeriae Galli, mume fructus and fructus Schisandrae respectively, pulverizing into 50 μm, mixing the powders with Trichosanthis radix, adding 8 times of 78% ethanol, ultrasonic extracting at 45KHz for 25min, filtering the extractive solution, recovering ethanol to obtain extractive solution, and concentrating at 55 deg.C to relative density of 1.1 to obtain first soft extract; steam distilling folium Mori, radix Ophiopogonis and herba Dendrobii with water at 110 deg.C for 3.5 hr, and filtering to obtain volatile oil extract; decocting fructus Lycii in water for 2 times, each time for 1.5 hr, to obtain decoction, and vacuum concentrating the decoction to obtain second soft extract; mixing the first soft extract, the volatile oil extract, and the second soft extract, adding bulking agent, stirring at 130r/min for 15min, drying at 53 deg.C for 24min, and making into granule.
Test results
160 are selected as experimenters, the ages are 40-60 years, the average age is 48.23 years, and the clinical manifestations are in vivo metabolic disorder, high blood sugar, high blood ketone and metabolic acidosis.
The experimenters are divided into 8 groups, and 1-8 groups take the traditional Chinese medicine composition prepared in the embodiments 1-8 of the invention in sequence, and the oral liquid taking method comprises the following steps: the medicine is taken 2 times a day for 7 days, 500mL is taken each time; the granule taking method comprises the following steps: the preparation is taken 2 times a day at a dose of 10g for 5 weeks; the physical condition of the experimenters is detected after 5 weeks, and the specific data are as follows:
TABLE 1 statistics of data
As can be seen from Table 1, examples 1-8 all had the effect of reducing blood glucose, lowering ketone bodies, restoring hemoglobin in vivo, and treating diabetic ketosis. Examples 1-2 compare examples 3-8, and examples 3-8 increase the number of raw materials and processing steps, and example 8 compares examples 3-7, and the effect of the Chinese medicinal composition obtained under the conditions of example 8 is better. Therefore, the traditional Chinese medicine composition can effectively treat diabetic ketosis.
In conclusion, the traditional Chinese medicine composition for treating diabetic ketosis provided by the embodiment of the invention can obviously reduce the blood sugar level of an organism, improve the immunity of the organism, improve the brain circulation and restore the normal metabolism of the organism, and has small side effect, so that the diabetic ketosis and the diabetes can be effectively treated. The invention can promote the drug effects of the raw materials to each other through the reasonable proportion of the raw materials, and nourish the organism during treatment, thereby ensuring better treatment effect. Different extraction methods are adopted according to different raw materials, so that the extraction rate of effective components in the raw materials is higher, and the treatment effect of the traditional Chinese medicine composition is further enhanced.
The embodiments described above are some, but not all embodiments of the invention. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Claims (10)
1. The traditional Chinese medicine composition for treating diabetic ketosis is characterized by comprising the following raw materials in parts by weight: 10-30 parts of mulberry leaf, 30-50 parts of kudzu root, 20-30 parts of trichosanthes root, 15-30 parts of dwarf lilyturf tuber and 20-30 parts of wolfberry fruit.
2. The traditional Chinese medicine composition according to claim 1, further comprising 15-20 parts of radix pseudostellariae, 10-20 parts of dendrobe and 20-30 parts of codonopsis pilosula by weight.
3. The traditional Chinese medicine composition as claimed in claim 2, further comprising 30-50 parts of astragalus membranaceus, 30-50 parts of Chinese yam, 30-50 parts of poria cocos, 10-30 parts of epimedium, 20-30 parts of salvia miltiorrhiza, 30-50 parts of endothelium corneum gigeriae galli, 30-50 parts of dark plum and 20-30 parts of schisandra chinensis by weight.
4. The traditional Chinese medicine composition of claim 3, wherein the preparation formulation of the traditional Chinese medicine composition is oral liquid or granules.
5. The Chinese medicinal composition according to claim 4, wherein the preparation method of the oral liquid comprises the following steps:
adding 2000mL of 1000-fold water into folium mori, radix puerariae, radix trichosanthis, radix ophiopogonis, fructus lycii, radix pseudostellariae, dendrobe and radix codonopsis pilosulae for decoction, boiling for 10-15min by strong fire, then decocting for 20-30min by slow fire, filtering to obtain a first decoction and filter residue, adding 1000mL of 500-fold water into the filter residue for decoction, decocting for 15-25min by slow fire after boiling by strong fire, filtering to obtain a second decoction, and combining the two decoctions.
6. The traditional Chinese medicine composition according to claim 4, wherein the preparation method of the granules comprises the following steps:
mixing radix Puerariae, radix Pseudostellariae, radix Codonopsis and Trichosanthis radix, adding 5-10 times of 70-80% ethanol, performing ultrasonic extraction at 40-60KHz for 20-30min, filtering the extractive solution, recovering ethanol to obtain extractive solution, and concentrating the extractive solution at 50-60 deg.C to obtain first soft extract with relative density of 1-1.23; adding water into folium Mori, radix Ophiopogonis and herba Dendrobii, steam distilling at 100-; decocting fructus Lycii in water for 1-2 times, each time for 1-2 hr, to obtain decoction, and vacuum concentrating the decoction to obtain second soft extract; mixing the first soft extract, the volatile oil extract, and the second soft extract, adding bulking agent, drying at 50-60 deg.C for 15-30min, and drying to obtain the granule.
7. The composition of claim 6, wherein the filler is one of starch, sugar powder and dextrin.
8. The Chinese medicinal composition as claimed in claim 6, wherein the preparation method further comprises pulverizing the mixture of radix Puerariae, radix Pseudostellariae and radix Codonopsis to a particle size of 50-60 μm before mixing.
9. The traditional Chinese medicine composition of claim 6, wherein, during steam distillation, the ratio of the mass of the water to the total mass of the mulberry leaves, the dwarf lilyturf turber and the dendrobium nobile is (4-7): 1.
10. the composition as claimed in claim 6, further comprising stirring at 150r/min for 10-20min at 100-.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210038899.0A CN114224973A (en) | 2022-01-13 | 2022-01-13 | Traditional Chinese medicine composition for treating diabetic ketosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210038899.0A CN114224973A (en) | 2022-01-13 | 2022-01-13 | Traditional Chinese medicine composition for treating diabetic ketosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114224973A true CN114224973A (en) | 2022-03-25 |
Family
ID=80746442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210038899.0A Pending CN114224973A (en) | 2022-01-13 | 2022-01-13 | Traditional Chinese medicine composition for treating diabetic ketosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114224973A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1443544A (en) * | 2002-03-07 | 2003-09-24 | 张世均 | Chinese medicine Jiangtang Tongmailing for curing diabetes and preventing and curing complicating diseases and its preparation method |
| CN101007137A (en) * | 2007-01-24 | 2007-08-01 | 张光珍 | 'Qimailing' oral liquid and its preparation method |
| CN102188612A (en) * | 2011-05-15 | 2011-09-21 | 袁成辰 | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof |
| CN104524194A (en) * | 2015-01-21 | 2015-04-22 | 康自兵 | Traditional Chinese medicine composition for treating diabetes |
| CN108434242A (en) * | 2018-06-22 | 2018-08-24 | 中南民族大学 | A kind of pharmaceutical composition, preparation method and its usage for treating diabetes and its complication |
| CN108567913A (en) * | 2018-07-26 | 2018-09-25 | 李茂辉 | A kind of drug and preparation method thereof for treating diabetes |
-
2022
- 2022-01-13 CN CN202210038899.0A patent/CN114224973A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1443544A (en) * | 2002-03-07 | 2003-09-24 | 张世均 | Chinese medicine Jiangtang Tongmailing for curing diabetes and preventing and curing complicating diseases and its preparation method |
| CN101007137A (en) * | 2007-01-24 | 2007-08-01 | 张光珍 | 'Qimailing' oral liquid and its preparation method |
| CN102188612A (en) * | 2011-05-15 | 2011-09-21 | 袁成辰 | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof |
| CN104524194A (en) * | 2015-01-21 | 2015-04-22 | 康自兵 | Traditional Chinese medicine composition for treating diabetes |
| CN108434242A (en) * | 2018-06-22 | 2018-08-24 | 中南民族大学 | A kind of pharmaceutical composition, preparation method and its usage for treating diabetes and its complication |
| CN108567913A (en) * | 2018-07-26 | 2018-09-25 | 李茂辉 | A kind of drug and preparation method thereof for treating diabetes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103285231B (en) | Medicine composition for diabetes adjunctive therapy and preparation method thereof | |
| CN104288501A (en) | Blood glucose reducing particle and preparation method thereof | |
| CN111956753B (en) | Medicinal and edible traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN103446385A (en) | Traditional Chinese medicine preparation for treating diabetic complications | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN103749822A (en) | Fructus ligustri lucidi health-care tea for lowering blood pressure and lipid and preparation method thereof | |
| CN104208581A (en) | Schisandra chinensis health care oral liquid capable of preventing alcoholic liver and preparation method thereof | |
| CN103637179B (en) | Food composition with functions of lowering blood sugar and blood fat and improving fatty liver | |
| CN105708970B (en) | A kind of health food with function of blood sugar reduction | |
| CN104857154A (en) | Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor | |
| CN108813501A (en) | With the relieving cough and reducing sputum health honey paste relievingd asthma and adjust function of human body of clearing heat and moistening lung | |
| CN106109521A (en) | A kind of Radix Notoginseng oral liquid | |
| CN103989996A (en) | Traditional Chinese medicine composition for treating diabetes and preparation method thereof | |
| CN112402569A (en) | Anti-fatigue health product and preparation method thereof | |
| CN114224973A (en) | Traditional Chinese medicine composition for treating diabetic ketosis | |
| CN111658720A (en) | Traditional Chinese medicine composition for health preservation, health preserving pill and preparation method | |
| CN110916036A (en) | Liquor and preparation method thereof | |
| CN111888431A (en) | Composition for treating diabetes and preparation method thereof | |
| CN111529598A (en) | Traditional Chinese medicine composition for nourishing vitality and tonifying qi and preparation method thereof | |
| CN108853340A (en) | A kind of Chinese medicine of nourishing the liver and kidney and preparation method thereof | |
| CN114949114B (en) | Agilawood-containing traditional Chinese medicine composition for enhancing immunity as well as preparation method, preparation and application thereof | |
| CN114796417B (en) | Blood sugar reducing traditional Chinese medicine formula and preparation method thereof | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
| CN107753589B (en) | A Chinese medicinal composition for treating diabetes, and its preparation method | |
| CN105878732A (en) | Traditional Chinese medicine for curing diabetes and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220325 |
|
| RJ01 | Rejection of invention patent application after publication |